AVROBIO

AVROBIO awarded Johnson & Johnson JLabs Incubator Space

Monday, May 16, 2016

AVROBIO, a clinical-stage biotechnology company developing transformative, life-changing gene therapies targeting rare diseases and cancer, has been awarded lab space at Johnson & Johnson’s (J&J) newest JLABS facility in Toronto, Ontario. AVROBIO, headquartered in Cambridge, Massachusetts, with researchers in Toronto, will join other early stage companies in the 40,000 square foot facility opening this spring.

[Read More]

AVROBIO launches in Cambridge, Massachusetts

Friday, February 19, 2016

AVROBIO, a clinical-stage biotechnology company developing transformative cell and gene therapies targeting cancer and rare diseases, has announced its launch plans. The company’s priority is to accelerate development of two novel cell and gene therapies pioneered within the labs of Dr. Christopher Paige and Dr. Jeffrey Medin (now at the Medical College of Wisconsin) at the University Health Network (UHN) in Toronto. Phase I programs will be in the clinic by early to mid-2016 in both acute myeloid leukemia (AML) and Fabry disease. The company will simultaneously work to expand its proprietary cell and gene therapy platform to treat additional indications.

[Read More]